Neuroimmunology Group, Department of Functional and Systems Neurobiology, Instituto Cajal, Consejo Superior de Investigaciones Científicas, Madrid, Spain.
Neurobiol Dis. 2010 Jan;37(1):166-76. doi: 10.1016/j.nbd.2009.09.020. Epub 2009 Oct 6.
The aim of this study was to evaluate how endocannabinoids interact with excitotoxic processes both in vitro, using primary neural cell cultures, and in vivo, in the TMEV-IDD model of multiple sclerosis. First, we observed that neuronal cells respond to excitotoxic challenges by the production of endocannabinoid molecules which in turn exerted neuroprotective effects against excitotoxicity. The inhibitor of endocannabinoid uptake, UCM707, protected specifically against AMPA-induced excitotoxicity, by activating CB(1) and CB(2) cannabinoid receptors, as well as the nuclear factor, PPARgamma. This neuroprotective effect was reverted by blocking the glial glutamate transporter, GLT-1. Mice subjected to the model of multiple sclerosis showed a decrease in the expression of GLT-1. UCM707 reversed this loss of GLT-1 and induced a therapeutic effect. Our data indicate that the enhancement of the endocannabinoid tone leads to neuroprotection against AMPA-induced excitotoxicity and provides therapeutic effects in this model of multiple sclerosis.
本研究旨在评估内源性大麻素与体外原代神经细胞培养和体内 TMEV-IDD 多发性硬化模型中兴奋性毒性过程的相互作用。首先,我们观察到神经元细胞对兴奋性毒性挑战产生内源性大麻素分子,这些分子反过来对兴奋性毒性发挥神经保护作用。内源性大麻素摄取抑制剂 UCM707 通过激活 CB(1)和 CB(2)大麻素受体以及核因子 PPARγ,特异性地对抗 AMPA 诱导的兴奋性毒性。这种神经保护作用通过阻断神经胶质谷氨酸转运体 GLT-1 而被逆转。多发性硬化症模型中的小鼠表现出 GLT-1 表达减少。UCM707 逆转了这种 GLT-1 的丢失,并诱导了治疗效果。我们的数据表明,内源性大麻素张力的增强导致对 AMPA 诱导的兴奋性毒性的神经保护,并在这种多发性硬化症模型中提供治疗效果。